- Report
- August 2022
- 117 Pages
Global
From €4378EUR$4,500USD£3,751GBP
- Clinical Trials
- May 2020
- 194 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Clinical Trials
- May 2020
- 878 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Clinical Trials
- December 2019
- 362 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Report
- May 2022
- 37 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- May 2022
- 46 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- May 2022
- 127 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- May 2023
- 160 Pages
Global
From €5837EUR$5,999USD£5,000GBP
- Report
- April 2023
- 147 Pages
Global
From €5837EUR$5,999USD£5,000GBP
- Report
- April 2023
- 147 Pages
Global
From €5837EUR$5,999USD£5,000GBP
- Report
- March 2023
- 147 Pages
Global
From €5837EUR$5,999USD£5,000GBP
- Report
- January 2022
- 137 Pages
Global
From €4378EUR$4,500USD£3,751GBP
The Seizure Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Seizure Drugs are used to treat epilepsy, a neurological disorder characterized by recurrent seizures. These drugs work by reducing the frequency and severity of seizures, and can be administered orally, intravenously, or rectally. Commonly used Seizure Drugs include anticonvulsants, benzodiazepines, and barbiturates.
Seizure Drugs are typically prescribed by neurologists and other healthcare professionals. The market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the Seizure Drug market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more
